Interleukin-2 promotes pegylated interferon alpha for hepatitis B surface antigen loss: A retrospective pragmatic clinical study at the Fourth Affiliated Hospital of Zhejiang University Medical College.

Health Sci Rep · 2022 · PMC9662690 · PMID 36381411

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

According to existing clinical data, we also found that although the overall clinical prognosis showed a trend of improvement after IL‐2 intervention in both clusters of patients, the difference in prognostic benefits was significant only after 1 week of IL‐2 intervention between the clusters.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.